☆ 4.3 Article

Biosimilar Use Among 38 ASCO PracticeNET Practices, 2019-2021

JCO ONCOLOGY PRACTICE (2023)

Related references

Note: Only part of the references are listed.

Article Oncology

Use of Biosimilar Medications in Oncology

Zeina Nahleh et al.

Summary: This report provides an update on currently approved oncology biosimilars and identifies knowledge gaps in the management of cancer patients. Despite years of clinical experience, there are variations in the use of oncology biosimilars. ASCO supports considering biosimilars and reference products equally effective and suggests their use as cost-effective alternatives in cancer care.

JCO ONCOLOGY PRACTICE (2022)

Add to Collection

Article Oncology

Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Guideline Update

Neelima Denduluri et al.

Summary: The study recommends offering 14 cycles of adjuvant T-DM1 to patients with HER2-positive breast cancer with pathologic invasive residual disease after standard preoperative chemotherapy and HER2-targeted therapy, based on the results of the KATHERINE trial.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Article Economics